Cell cycle biology of fibrolamellar hepatocellular carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 8, 2010, Pages 792-797

  Dhingra, Sadhna ^a   Li, Wei ^a   Tan, Dongfeng ^b   Zenali, Maryam ^b   Zhang, Haizeng ^b   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell cycle; Chemoresistance; Fibrolamellar hepatocellular carcinoma; Immunohistochemistry; Liver; P16ink4

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MITOSIS INDEX; PATHOLOGY; PROGNOSIS;

ADULT; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MITOTIC INDEX; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79953131570     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007; 14(3):217-223.
2. Liu S, Chan KW, Wang B, et al. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009; 104(10):2617-2624.
3. Li W, Tan D, Zenali MJ, et al. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol. 2009; 3(3):238-243.
4. Zenali MJ, Tan D, Li W, et al. Stemness characteristics of fibrolamellar hepatocellular carcinoma: Immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. Ann Clin Lab Sci. 2010; 40(2) 126-134.
5. Hui AM, Makuuchi M. Molecular basis of multistep hepatocarcinogenesis: genetic and epigenetic events. Scand J Gastroenterol. 1999; 34(8):737-742.
6. Matsuda Y. Molecular mechanism underlying the functional loss of cyclin dependent kinase Inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol. 2008; 14 (11):1734-1740.
7. Chiarle R, Fan Y, Piva R, et al. S-phase kinase associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cell in S phase. Am J Pathol. 2002; 160: 1457-1466.
8. Johansson M, Persson JL. Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem. 2008; 8 (7):723-731.
9. Matsuda Y, Ichida T. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med Mol Morphol. 2006; 39 (4):169-175.
10. Hui AM, Makuuchi M, Li X. Cell cycle regulators and human hepatic carcinogenesis. Hepatogastroenterology. 1998; 45(23):1635-1642.
11. Wiesner T, Obenauf AC, Cota C, et al. Alterations of the Cell-Cycle Inhibitors p27 (KIP1) and p16 (INK4a) are frequent in Blastic Plasmacytoid Dendritic Cell Neoplasms. J Invest Dermatol. 2010; 130(4): 1152-1157.
12. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-166.
13. Viallard JF, Lacombe F, Belloc F, et al. Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology. Cancer Radiother. 2001; 5(2):109-129.
14. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003; 36(3):131-149.
15. Kamb A. Cyclin dependent kinase inihibitors and human cancer. Curr. Top. Microbiol. Immunol. 1998; 227,139.
16. Hall M, Peters G. Genetic alterations in cyclins, cyclin dependent kinases and CDK inhibitors in human cancer. Adv Cancer Res.1996; 68; 67.
17. Biden K, Young J, Buttenshaw R, et al. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology. 1997; 25(3):593-597
18. Chaubert P, Gayer R, Zimmermann A, et al. Germ -line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology. 1997; 25 (6):1376-1381.
19. Jin M, Piao Z, Kim NG, et al. p 16 is a major inactivation target in hepatocellular carcinoma. Cancer. 2000; 89 (1):60-68.
20. Matsuda Y, Ichida T, Matsuzawa J, et al. p16 (INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology. 1999; 116(2):394-340.
21. Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol. 2008; 21(6):670-675.
22. Kakar S, Chen X, Ho C, et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol. 2009; 22(1):134-141.
23. Terraciano LM, Tornillo L, Avolado P. et al. Fibrolamellar hepatocellular carcinoma occuring 5 years after hepatocellular adenoma in a 14 year old girl: a case report with comparative genomic hybridization analysis. Arch Pathol Lab Med. 2004; 128:222-226.
24. Marchio A, Pineau P, Meddeb M. et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene. 2000; 19:3733-3738.
25. Wilkens L, Bredt M., Flemming P. et al. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol. 2000; 114: 867-874.